U.S. markets closed
  • S&P 500

    3,901.82
    +90.67 (+2.38%)
     
  • Dow 30

    31,535.51
    +603.14 (+1.95%)
     
  • Nasdaq

    13,588.83
    +396.48 (+3.01%)
     
  • Russell 2000

    2,275.32
    +74.27 (+3.37%)
     
  • Crude Oil

    59.94
    -0.70 (-1.15%)
     
  • Gold

    1,722.40
    -0.60 (-0.03%)
     
  • Silver

    26.58
    -0.09 (-0.35%)
     
  • EUR/USD

    1.2051
    -0.0009 (-0.07%)
     
  • 10-Yr Bond

    1.4460
    -0.0140 (-0.96%)
     
  • GBP/USD

    1.3931
    +0.0011 (+0.08%)
     
  • USD/JPY

    106.8310
    +0.1010 (+0.09%)
     
  • BTC-USD

    49,918.46
    +4,095.23 (+8.94%)
     
  • CMC Crypto 200

    982.63
    +54.40 (+5.86%)
     
  • FTSE 100

    6,588.53
    +105.10 (+1.62%)
     
  • Nikkei 225

    29,888.67
    +225.17 (+0.76%)
     

Return On Capital Employed Overview: Unity Biotechnology

  • Oops!
    Something went wrong.
    Please try again later.
Benzinga Insights
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

During Q2, Unity Biotechnology (NASDAQ: UBX) saw earnings decrease by 14.02%, resulting in a loss of $23.35 million. In Q1, Unity Biotechnology lost $27.16 million in earnings.

Why ROCE Is Significant

Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed in a business. Changes in earnings and sales indicate shifts in a company's ROCE. A higher ROCE is generally representative of successful growth in a company and is a sign of higher earnings per share for shareholders in the future. A low or negative ROCE suggests the opposite. In Q2, Unity Biotechnology posted an ROCE of -0.21%.

Keep in mind, while ROCE is a good measure of a company's recent performance, it is not a highly reliable predictor of a company's earnings or sales in the near future.

View more earnings on UBX

Return on Capital Employed is an important measurement of efficiency and a useful tool when comparing companies that operate in the same industry. A relatively high ROCE indicates a company may be generating profits that can be reinvested into more capital, leading to higher returns and growing EPS for shareholders.

In Unity Biotechnology's case, the ROCE ratio shows the amount of assets may not be helping the company achieve higher returns. Investors may take this into account before making any long-term financial decisions.

Q2 Earnings Insight

Unity Biotechnology reported Q2 earnings per share at $-0.38/share, which beat analyst predictions of $-0.51/share.

See more from Benzinga

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.